# Antiviral Effects of TXA as a Preventative Treatment Following COVID-19 Exposure

> **NCT04550338** · PHASE3 · WITHDRAWN · sponsor: **University of Alabama at Birmingham**

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Tranexamic acid
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04550338
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-08-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** With vaccination efforts ongoing, a feasibility survey indicated there would be inadequate recruitment
- **Last updated:** 2021-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04550338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04550338, "Antiviral Effects of TXA as a Preventative Treatment Following COVID-19 Exposure". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04550338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*